Compare ProShares UltraPro QQQ ETF (TQQQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ProShares UltraPro QQQ ETF trades at $74.46, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| TQQQ | VRTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $529.65 |
52-Week Low | $37.89 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $75.13, up 1.82% with a bullish technical signal supported by moving averages. The ETF leverages Nasdaq-100 exposure, amplified by 3x daily returns. Recent institutional buying includes Bay Colony Advisory's 7,786 share acquisition. Technical indicators show RSI at 74.38 suggesting overbought conditions, while ADX indicates strong trend momentum. Support levels begin at $72 with resistance at $74-$76.
Outlook remains positive given AI-driven tech momentum, but leverage amplifies volatility risks. The ETF's structural costs compound daily, potentially eroding long-term returns despite short-term gains. Investors face significant downside risk during market corrections, as evidenced by recent 14% single-day declines. Current levels warrant caution despite bullish technicals.
Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.
Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
